Isolation of a new broad spectrum antifungal polyene from Streptomyces sp. MTCC 5680. 2014

A Vartak, and V Mutalik, and R R Parab, and P Shanbhag, and S Bhave, and P D Mishra, and G B Mahajan
Department of Natural products-Biology, Piramal Enterprises Limited, Mumbai, India.

A new polyene macrolide antibiotic PN00053 was isolated from the fermentation broth of Streptomyces sp. wild-type strain MTCC-5680. The producer strain was isolated from fertile mountain soil of Naldehra region, Himachal Pradesh, India. The compound PN00053 was purified through various steps of chromatographic techniques and bio-activity guided fractionation followed by its characterization using physiochemical properties, spectral data ((1) H-NMR, (13) C-NMR, HMBC, HSQC, and COSY) and MS analysis. PN00053 exhibited broad spectrum in vitro antifungal activity against strains of Aspergillus fumigatus (HMR), A. fumigatus ATCC 16424, Candida albicans (I.V.), C. albicans ATCC 14503, C. krusei GO6, C. glabrata HO4, Cryptococcus neoformans, Trichophyton sp. as well as fluconazole resistant strains C. krusei GO3 and C. glabrata HO5. It did not inhibit growth of gram positive and gram-negative bacteria, displaying its specificity against fungi. CONCLUSIONS PN00053 is a novel polyene macrolide isolated from a wild strain of Streptomyces sp. PM0727240 (MTCC5680), an isolate from the mountainous rocky regions of Himachal Pradesh, India. The compound is a new derivative of the antibiotic Roflamycoin [32, 33-didehydroroflamycoin (DDHR)]. It displayed broad spectrum antifungal activity against yeast and filamentous fungi. However, it did not show any antibacterial activity. The in vitro study revealed that PN00053 has better potency as compared to clinical gold standard fluconazole. The development of pathogenic resistance against the polyenes has been seldom reported. Hence, we envisage PN00053 could be a potential antifungal lead.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011090 Polyenes Hydrocarbons with more than one double bond. They are a reduced form of POLYYNES. Cumulenes
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D003455 Cryptococcus neoformans A species of the fungus CRYPTOCOCCUS. Its teleomorph is Filobasidiella neoformans. Blastomyces neoformans,Debaryomyces neoformans,Filobasidiella neoformans,Lipomyces neoformans,Saccharomyces neoformans,Torula neoformans,Torulopsis neoformans,Cryptococcus neoformans var. grubii
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000898 Antibiosis A natural association between organisms that is detrimental to at least one of them. This often refers to the production of chemicals by one microorganism that is harmful to another. Bacterial Interference,Microbial Antagonism,Interference, Bacterial,Antagonism, Microbial,Antagonisms, Microbial,Antibioses,Bacterial Interferences,Interferences, Bacterial,Microbial Antagonisms
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D001232 Aspergillus fumigatus A species of imperfect fungi from which the antibiotic fumigatin is obtained. Its spores may cause respiratory infection in birds and mammals. Aspergillus fumigates,Neosartorya fumigata,Sartorya fumigata
D012988 Soil Microbiology The presence of bacteria, viruses, and fungi in the soil. This term is not restricted to pathogenic organisms. Microbiology, Soil
D013302 Streptomyces A genus of bacteria that form a nonfragmented aerial mycelium. Many species have been identified with some being pathogenic. This genus is responsible for producing a majority of the ANTI-BACTERIAL AGENTS of practical value.

Related Publications

A Vartak, and V Mutalik, and R R Parab, and P Shanbhag, and S Bhave, and P D Mishra, and G B Mahajan
August 2023, Journal of natural products,
A Vartak, and V Mutalik, and R R Parab, and P Shanbhag, and S Bhave, and P D Mishra, and G B Mahajan
June 2008, Journal of microbiology (Seoul, Korea),
A Vartak, and V Mutalik, and R R Parab, and P Shanbhag, and S Bhave, and P D Mishra, and G B Mahajan
May 2012, Journal of natural products,
A Vartak, and V Mutalik, and R R Parab, and P Shanbhag, and S Bhave, and P D Mishra, and G B Mahajan
January 1983, Chemotherapy,
A Vartak, and V Mutalik, and R R Parab, and P Shanbhag, and S Bhave, and P D Mishra, and G B Mahajan
January 2019, Frontiers in microbiology,
A Vartak, and V Mutalik, and R R Parab, and P Shanbhag, and S Bhave, and P D Mishra, and G B Mahajan
February 2009, Organic letters,
A Vartak, and V Mutalik, and R R Parab, and P Shanbhag, and S Bhave, and P D Mishra, and G B Mahajan
January 1971, Zeitschrift fur allgemeine Mikrobiologie,
A Vartak, and V Mutalik, and R R Parab, and P Shanbhag, and S Bhave, and P D Mishra, and G B Mahajan
March 2005, Journal of biosciences,
A Vartak, and V Mutalik, and R R Parab, and P Shanbhag, and S Bhave, and P D Mishra, and G B Mahajan
June 2007, Expert opinion on pharmacotherapy,
A Vartak, and V Mutalik, and R R Parab, and P Shanbhag, and S Bhave, and P D Mishra, and G B Mahajan
September 1986, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!